Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...

Cell therapy brings a new dimension to the personalization of cancer care. These treatments are currently made by engineering a patient’s own immune cells into better and more targeted cancer fighters ...

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.

Lonza and Celladon, a biotechnology firm specializing in cardiovascular gene therapy, have entered an agreement that could elevate a multiyear clinical manufacturing contract for Celladon’s Mydicar ...